Clinical trial
Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib…
NCT00287092 · Sanofi Pasteur, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00287092 |
|---|---|
| Title | Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants |
| Official title | A Randomised, Controlled, Double-Blind Study of the Immunogenicity and Safety of PEDIACEL®, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus Influenzae Type b Conjugate Vaccine (Adsorbed) Compared To Infanrix®-IPV+Hib When Both Vaccines… |
| Lead sponsor | Sanofi Pasteur, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pertussis, Diphtheria, Tetanus, Poliomyelitis, Haemophilus Influenzae Type b |
| Intervention type | Biological |
| Interventions | DT5aP-IPV-Hib 5-component Pertussis vaccine, Infanrix® -IPV+Hib |
| Enrollment | 807 |
| Start date | Feb 1, 2006 |
| Primary completion | May 1, 2007 |
| Completion | Sep 1, 2008 |
| First posted | Feb 6, 2006 |
| Last update posted | Jan 7, 2015 |
| Countries | Finland, Sweden |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: